Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | The future of ravulizumab in NMOSD

Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, describes how ravulizumab’s properties are likely to replace eculizumab in neuromyelitis optica spectrum disorder (NMOSD). This is because, although eculizumab has been successful and effective, the requirement of an infusion every two weeks is logistically challenging as these patients have mobility issues, and there could be issues related to traveling to the infusion centers. Ravulizumab requires infusion every eight weeks, which is much more doable and, alongside its reduced cost, makes it very likely to replace eculizumab in treatment. This interview took place at the AAN Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Levy receives consulting fees from Alexion, which is the manufacturer of ravulizumab, as well as other companies that make medications for NMOSD including Horizon (Amgen), and Genentech (Roche).